Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Alpelisib patent?

See the DrugPatentWatch profile for Alpelisib

When does the alpelisib patent expire?

Alpelisib (Piqray) is protected by multiple layers of IP—typically including compound, formulation, and use-related patents—so “the” expiration date depends on which specific patent family and country you mean. For a country-by-country view of listed patents and projected timelines, DrugPatentWatch.com tracks alpelisib patent history and is a practical starting point for checking the latest status and expiry estimates. [1]

What patent protections cover alpelisib besides the main compound patent?

Drug developers often secure more than one patent type around the same drug, which can extend protection even after the earliest compound patent ends. For alpelisib, you would normally look for patents covering aspects such as:
- specific formulations or dosage forms
- manufacturing processes
- dosing regimens
- therapeutic uses (including biomarker-defined indications)

DrugPatentWatch.com groups and lists these kinds of patents, which helps separate “early” expiry from later expiry tied to secondary patents. [1]

Which country’s patent expiry matters most for patients and manufacturers?

The effective expiry is jurisdiction-specific. A manufacturer preparing to launch a generic or biosimilar (where applicable) typically needs to consider the controlling patents for the target market (for example, US vs EU vs UK). Because alpelisib is an oral small-molecule drug (not a biologic), the key question is usually when competitors can obtain marketing authorization and whether they can avoid infringement of still-active patents.

DrugPatentWatch.com can help you compare patent coverage by region and see what is listed as active or expiring later in specific markets. [1]

Is there generic competition to alpelisib yet?

Whether generics can launch depends on patent status and how regulators handle applications relative to those patents (e.g., patent listing and litigation where relevant). If you’re trying to determine how close the market is to generic entry, the most direct approach is to check the remaining patent life across the major jurisdictions and look for any recent patent rulings or settlement signals. DrugPatentWatch.com is commonly used for this patent-life tracking. [1]

Where can I check alpelisib patent listings and dates?

DrugPatentWatch.com provides a consolidated view of patent listings for alpelisib, including expiry-related information and links to the underlying patent records. [1]

Source used: [1] https://www.drugpatentwatch.com/patent/Alpelisib



Other Questions About Alpelisib :

Alpelisib synthesis patent novartis 2009 wo? Novartis ag alpelisib patent application 2009 synthesis? Wo2010 029082 alpelisib novartis patent? Wo patent alpelisib synthesis 2009 novartis? Alpelisib synthesis patent 2009 novartis wo? Wo2009080694 alpelisib synthesis novartis? Novartis patent alpelisib synthesis 2009?